Aug. 19 at 1:34 PM
$GNPX There's a lot of wrong info circulating on Genprex right now. I hold a small flyer, so I spent the last few days in the actual filings instead of the timeline.
TLDR... the negative enterprise value is real. So is the reason it's negative. Share count is up 447% in 7 months, and yesterday's CDMO "milestone" was filed as Item 8.01, not a material agreement.
Heads up. Long post, sources at the bottom. If you just want the God candle, LOL, I get it... no judgment, scroll on.
The capital structure is the whole story
Start with the share count, b/c nothing else makes sense until you have it. Most Nasdaq biotechs at this valuation carry tens of millions of shares... that's the frame people bring with them, and it's why the market cap here looks like a typo. Genprex has 819,709 shares outstanding as of Aug 10. Yep... Eight hundred nineteen thousand. Roughly one one-hundredth of what you'd assume for a name in this tier.
That's after a 1-for-50 reverse split in Oct 2025 and a 1-for-22 on July 16, 2026... cumulative 1-for-1,100 in 10 months. Every per-share number below is on that basis.
Bal sheet at Jun 30:
$15,154,203 cash, no debt,
$2,341,864 total liabilities,
$14,795,052 stockholders' equity. Operating burn for the half was
$8,277,156, about
$1.38M a month. Another ~
$1.53M came in off the ATM after quarter end, disclosed in Subsequent Events.
Net that out and current cash is somewhere near
$14.5M... my estimate, not a filed figure. Market cap at recent prices is roughly
$3.1–3.4M. So... EV neg by around
$11M.
That number is real. It's also where most of the commentary stops, and stopping there is how people get hurt, IMO.
Why the cash trades at a discount
Cash per share:
12/31/25 -
$52.27
6/30/26 -
$29.94
Today... roughly
$17.69 (estimated)
Cash nearly doubled over that stretch. Cash per share fell about two thirds. Share count went from 149,811 to 819,709 in 7 months on a split-adjusted basis. Up 447%.
The ATM did that. There's a
$12.5M Lincoln Park equity line with no draws in the first half of 2026, and a new S-3 shelf filed Jun 5. Note 1 of the 10-Q states substantial doubt as to the company's ability to continue as a going concern, with cash expected to fund ops into the second half of 2027.
So the neg EV isn't a mispricing waiting to be arbitraged. It's the market pricing the mechanism by which that cash becomes float. Both readings can be defended. Only one of them accounts for the last 7 months.
Warrant overhang is a non-issue, fwiw -- 60,008 warrants at a weighted avg strike of
$554.17, lowest strike
$192.50. Nothing there is coming into the money. The dilution channel is the ATM, full stop.
Yesterday's CDMO announcement
On Aug 18 Genprex announced a development and manufacturing agreement with an unnamed U.S. CDMO to scale up the diabetes program.
It was filed as an 8-K under Item 8.01, Other Events. Not Item 1.01, Entry into a Material Definitive Agreement. No counterparty named, no contract exhibit, no economics, no milestones. Item 1.01 is the mandatory disclosure for a material contract and normally requires the agreement itself as an exhibit. The company filed under the voluntary catch-all instead. That's Genprex telling you how material it considers this.
There's also overlap with prior disclosure. The Jan 7, 2026 release already stated the manufacturing process had been transferred from academic collaborators to CDMOs. The CEO quote in the new release says substantially the same thing.
And that quote refers to the diabetes "clinical program." Genprex's own pipeline slide places GPX-002 at Preclinical, one column short of IND-Enabling. Per the 10-Q, toxicology studies have not been initiated, and IND filing comes after tox data. That's the honest timeline.
The science, on its merits
I went back and forth on how hard to push this section, b/c the mechanism is the part I actually find interesting and I didn't want the bal sheet work to bury it.
AAV vector carrying Pdx1 and MafA, delivered directly into the pancreatic duct -- in humans, by routine endoscopy. In T1D it's designed to transform alpha cells into functional beta-like cells that produce insulin but may be distinct enough from beta cells to evade autoimmune attack. In T2D, where autoimmunity isn't a factor, it's believed to replenish and rejuvenate exhausted beta cells.
In T1D non-human primate models, the candidate decreased insulin requirements, increased c-peptide, and improved glucose tolerance. C-peptide is the endpoint that matters... it's evidence of endogenous insulin production, not just glucose control. T2D showed beta-cell effects in both mouse and NHP models. That's the larger population and it gets almost no attention.
That said, preclinical is preclinical. Mouse and NHP models are where a lot of diabetes programs have looked excellent and then failed to translate.
Where the near-term catalysts actually are
Not diabetes. Acclaim-3 -- REQORSA plus Genentech's Tecentriq as maintenance in extensive-stage SCLC. Company expects to complete enrollment of the first 25 patients by end of 2026, with the interim futility analysis in the first half of 2027. Fast Track and Orphan Drug on that program.
Acclaim-1 (REQORSA + AstraZeneca's Tagrisso, EGFR-mutant NSCLC) is enrolling in the Phase 2a expansion. Fast Track. Worth noting from the Phase 1 data: one patient reached partial remission and held it through 66 courses of treatment before progressing at 47 months. Small n, but that's real durability.
The Roche Diagnostics collaboration to validate TROP2 for patient selection targets completion around end of 2026, using the same TROP2 antibody as Roche's FDA Breakthrough-designated NSCLC companion diagnostic. If it validates, biomarker-enriched enrollment changes the odds on the trial.
Convergen Biotech, the wholly-owned subsidiary formed in Feb 2025 for a potential diabetes separation, still had not initiated operating activity as of Jun 30. Dormant shell or optionality, depending on your read.
The honest summary
Bull case: genuinely negative enterprise value, float under a million shares, two Fast Track oncology programs with an interim readout inside twelve months, a Roche-adjacent biomarker catalyst, and a novel diabetes platform nobody is valuing.
Bear case: going concern doubt in the filings, an ATM that expanded the share count 447% in seven months with the Lincoln Park line and a fresh shelf still behind it, two reverse splits in 10 months, a diabetes lead asset that hasn't started tox, and an accumulated deficit of
$179.9M against no current source of revs.
Both are accurate. Neither cancels the other. If you buy the negative EV without pricing the issuance, you're not doing arbitrage... you're subsidizing the next raise.
Disclosure: small spec position, sized as capital I've written off. ALWAYS do your own DD. Not advice. Every figure above is from the 10-Q filed 8/14/26 and the related 8-Ks. Go read them yourself. Giddy up and GLTA.
